Use of methotrexate in rheumatoid arthritis
Abstract
The objective of the treatment of rheumatoid arthritis is to stop or at least delay, inflammation and joint damage. The disease modifying drugs are the cornerstone in the treatment of Rheumatoid Arthritis. The correct use of disease modifying drugs has improved the prognosis of RA, based on its early use and aiming of a specific therapeutic target. Methotrexate is considered the anchor treatment drug, it is recommended as the preferred drug at disease onset and in combination with other drugs during their evolution according to disease activity. The current review aims to provide guidance on the proper use of this drug in rheumatoid arthritis: initial dose, route of administration, dosage increase and decrease, patient monitoring, use of folic acid, special situations prior to and during treatment.Downloads
References
(1) AH, Breedveld FC, et al. Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: Comparison of two cohorts who received different treatment strategies. Am J Med. 2001:446-51.
(2) Nell VP, Machold KP, Eberl G, Stamm TA, Uffmann M, Smolen JS. Benefit of very early referral and very early therapy with diseasemodifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology (Oxford). 2004;43:906-14.
(3) Quinn MA, Conaghan PG, Emery P. The therapeutic approach of early intervention for rheumatoid arthritis: What is the evidence? R heumatology (Oxford). 2001;40:1211-20.
(4) J. Tornero Molina et al. Recomendaciones para el uso del metotrexatoen artritis reumatoide: incremento y reducción de dosis y vías de administración Reumatol Clin. 2015;11(1):3-8.
(5) Jasvinder A. singh, Kenneth G. Saag, S. Louis Bridges Jr., a. et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res. 2016;68:1-25.
(6) Josef S Smolen, Robert Landewé, Ferdinand C Breedveld et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2013;0:1-18.
(7) R . Sanmartí et al. Actualización 2014 del Documento de Consenso de la Sociedad Española de Reumatología sobre el uso de terapias biológicas en la artritis reumatoide. Reumatol Clin. 2015;11(5):279-294.
(8) Jurgens MS, Jacobs JW, Bijlsma JW. The use of conventional disease-modifying anti-rheumatic drugs in established RA. Best Pract Res Clin Rheumatol. 2011;25:523-33.
(9) Sociedad Española de Reumatología. Actualización de la guía practica para el manejo de la artritis reumatoide en España 2011. htpp://www.ser.es
(10) Furst D, Erikson N, Clute l, et al. Adverse experience with methotrexate during 176 week of a long term prospective trial in patients with rheumatoid arthritis. J Rheumatol. 1990;17:1628-35.
(11) Phillps CA, Cera PJ, Mangan TF, Newman ED, Clinical liver disease in patients with rheumatoid arthritis taking methotrexate. J Rheumatol. 1992;19:229-33.
(12) Hilliquin P, Renoux M, Perrot S, et al. Occurence of pulmonary complications during methotrexate therapy in Rheumatoid arhritis. Br J Rheumatol 1996; 35: 441-5
(13) Jurgens MS, Jacobs JW, Bijsma JW. The use of conventional disease-modifying anti-rheumatic drugs in establisherd RA. Best Pract Res Clin Rheumatol. 2011; 25 (4): 523-33.
(14) Singer O, Gibofsky A, Methotrexate versus leflunomide in rheumatoid arthritis. What is new. Curr Opin Rheumatol. 2011;23(3):288-92.
(15) Van Ede AE, Laan RF, Rood MJ, et al. Effect of folic or Folinic acid supplementation on the toxicity and efficacy of nethotrexate in rhreumatoid arthritis: a forty-eight week, multicenter, randomized, doublé-blind, placebo-cotroled study. Arthritis Rheum. 2001; 44:1515-24.
(16) Pavy S, Contantin A, Goseec l, et al. Methotrexate therapy for rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion. Joint Bone Spine. 2006;73(4):388-95.
(17) Alsufyani K, Ortiz-Alvarez O, Cabral DA, Tucker LB, Petty RE, Malleson PN. The role of subcutaneous administration of methotrexate in children with juvenile idiopathic arthritis who have failed oral methotrexate. J Rheumatol. 2004;31:179-82.
(18) Bingham SJ, Buch MH, Lindsay S, Pollard A, White J, Emery P. Parenteral methotrexate should be given before biological therapy. R heumatology (Oxford). 2003;42:1009-10.
(19) Verstappen SM, Jacobs JW, van der Veen MJ, Heurkens AH, Schenk Y, Ter Borg EJ, et al. Intensive treatment with methotrexate in early rheumatoid arthritis: Aiming for remission. Computer assisted management in early rheumatoid arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis. 2007;66:1443-9.
(20) Jassim IAH, Al-Allaf A, Newton P. Methotrexate in rheumatoid arthritis, starting dose and dose escalation regimens. Ann Rheum Dis. 2007;66:S440-1.
(21) Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): A single-blind randomised controlled trial. Lancet. 2004;364:263-9.
(22) Visser K, Katchamart W, Loza E, Martinez-Lopez JA, Salliot C, T rudeau J, et al. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: Integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3 E initiative. Ann Rheum Dis. 2009;68:1086-93.
(23) Fomin I, Caspi D, Levy V, Varsano N, Shalev Y, Paran D, et al. Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNF alpha blockers. Ann Rheum Dis. 2006;65(2):191-4
(24) Elkayam O, Paran D, Caspi D, Litinsky I, Yaron M, Charboneau D, et al. Immunogenicity and safety of pneumococcal vaccination in patients with rheumatoid arthritis or systemic lupus erythematosus. C lin Infect Dis. 2002;34(2):147-53.
(25) Kapetanovic MC, Saxne T, Sjoholm A, Truedsson L, Jonsson G, Geborek P. Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. Rheumatology (Oxford). 2006;45(1):106-11.
(26) Doran MF, Crowson CS, Pond GR, O‘Fallon WM, Gabriel SE. Predictors of infection in rheumatoid arthritis. Arthritis Rheum. 2002; 46(9):2294-300.
(27) Calabrese LH, Zein NN, Vassilopoulos D. Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies. Ann Rheum Dis. 2006;65(8): 983-9.
(28) Cepeda EJ, Williams FM, Ishimori ML, Weisman MH, Reveille JD. T he use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease. Ann Rheum Dis. 2008;67(5):710-2.
Copyright (c) 2016 Paraguayan Journal of Rheumatology
This work is licensed under a Creative Commons Attribution 4.0 International License.
